New drug combo tested for aggressive breast cancer before surgery
NCT ID NCT02623972
Summary
This study is testing whether adding the drug eribulin to standard chemotherapy works better when given before surgery for a specific aggressive type of breast cancer (HER2-negative inflammatory breast cancer). Researchers want to see if this drug sequence helps eliminate more cancer from the breast and lymph nodes by the time of surgery. The study involves 22 participants and compares two different orders of giving the medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.